Identification of the V factor needed for synthesis of the iron-molybdenum cofactor of nitrogenase as homocitrate

Nitrogenase catalyses the ATP-dependent reduction of N2 to NH3, and is composed of two proteins, dinitrogenase (MoFe protein or component I) and dinitrogenase reductase (Fe protein or component II). Dinitrogenase contains a unique prosthetic group (iron-molybdenum cofactor, FeMoco) comprised of Fe, Mo and S, which has been proposed as the site of N2 reduction. Biochemical and genetic studies of Nif- (nitrogen fixation) mutants of Klebsiella pneumoniae which are defective in nitrogen fixation, have shown that the nifB, nifQ, nifN, nifE and nifV genes are required for the biosynthesis of FeMo-co. Recently, a system for in vitro synthesis of FeMoco was described. The assay requires at least the nifB, nifN and nifE gene products, and a low-molecular-weight factor (V factor) produced in the presence of the nifV gene product. We have used this system to study FeMoco biosynthesis. We report here the isolation of V factor and identify it as homocitric acid ([R]2-hydroxy-1,2,4-butanetricarboxylic acid).     

‘High dose’ immunologic tolerance toEscherichia coli lipopolysaccharide assessed by bacteriolytic and hemolytic plaque assays

Zusammenfassung Immunologische Toleranz konnte in Mäusen durch hohe Dosen vonE. coli Lipopolysaccharid erreicht werden. Der Effekt war mit Hilfe der passiven hämolytischen «plaque»-Methode besser zu erfassen als im direkten bakteriologischen System.

---

---

Supported in part by grants from the U.S. National Science Foundation and the National Institutes of Health, Bethesda, Maryland.     

Rapid recruitment and proliferation of antibody plague-forming cells in the absence of natural antibody

Zusammenfassung Nachweis, dass «Plaque»-bildende Antikörperzellen gegen somatische Antigene vonVibrio cholerae sich in der Milz immunisierter Mäuse schnell und «treppenartig» nach übereinstimmender Latenzzeit von 42 h entwickeln, ohne dass dabei ein «background» an Antikörper bildenden Zellen zu erfassen war.     

The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells

A therapeutic strategy for treating cancer is to target and eradicate cancer stem cells (CSCs) without harming their normal stem cell counterparts. The success of this approach relies on the identification of molecular pathways that selectively regulate CSC function. Using BCR-ABL-induced chronic myeloid leukemia (CML) as a disease model for CSCs, we show that BCR-ABL downregulates the Blk gene (encoding B-lymphoid kinase) through c-Myc in leukemic stem cells (LSCs) in CML mice and that Blk functions as a tumor suppressor in LSCs but does not affect normal hematopoietic stem cells (HSCs) or hematopoiesis. Blk suppresses LSC function through a pathway involving an upstream regulator, Pax5, and a downstream effector, p27. Inhibition of this Blk pathway accelerates CML development, whereas increased activity of the Blk pathway delays CML development. Blk also suppresses the proliferation of human CML stem cells. Our results show the feasibility of selectively targeting LSCs, an approach that should be applicable to other cancers.     

Antigen Binding rosette forming cells in a friend virus-induced leukemia

Résumé Les souris infectées par le virus de la leucémie de Friend avaient le meme nombre de cellules spléniques capables de se lier à des érythrocytes de mouton grâc à un récepteur immunolgobuline que les souris normales, non infectées, et servant de contrôle, possédent également. De plus, les souris infectées par le virus répondent à l'immunisation par des érythrocytes de mouton defacon nettement diminuée.     

A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis

Chronic pancreatitis is a common inflammatory disease of the pancreas. Mutations in the genes encoding cationic trypsinogen (PRSS1) and the pancreatic secretory trypsin inhibitor (SPINK1) are associated with chronic pancreatitis. Because increased proteolytic activity owing to mutated PRSS1 enhances the risk for chronic pancreatitis, mutations in the gene encoding anionic trypsinogen (PRSS2) may also predispose to disease. Here we analyzed PRSS2 in individuals with chronic pancreatitis and controls and found, to our surprise, that a variant of codon 191 (G191R) is overrepresented in control subjects: G191R was present in 220/6,459 (3.4%) controls but in only 32/2,466 (1.3%) affected individuals (odds ratio 0.37; P = 1.1 x 10(-8)). Upon activation by enterokinase or trypsin, purified recombinant G191R protein showed a complete loss of trypsin activity owing to the introduction of a new tryptic cleavage site that renders the enzyme hypersensitive to autocatalytic proteolysis. In conclusion, the G191R variant of PRSS2 mitigates intrapancreatic trypsin activity and thereby protects against chronic pancreatitis.